Morgan Stanley Histogen Inc. Transaction History

Morgan Stanley

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.39 - $0.88 $3,159 - $7,128	-8,100 Reduced 50.31%	8,000 $4,000
Q2 2023 Aug 14, 2023	BUY	$0.71 - $1.22 $11,431 - $19,642	16,100 New	16,100 $11,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $3.76 $3,399 - $9,682	2,575 New	2,575 $3,000

Ticker HSTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,497,450
Market Cap $49.9K
Description
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.